Liquidia Corporation
LQDA
Rank in Stocks
#4469
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Share Price
$38.75
Market Cap
$3.47B
Change (1 day)
6.60%
Change (1 year)
64.26%
Country
US
Trade Liquidia Corporation (LQDA)
Category
Healthcare
Stock price history for Liquidia Corporation (LQDA)
Highest end of day price: $30.60 on 2026-10-01
Lowest end of day price: $11.01 on 2018-07-01
Lowest end of day price: $11.01 on 2018-07-01
Stock price history of Liquidia Corporation from 2018 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | 42.69% |
| 2025 | 204.28% |
| 2024 | 26.82% |
| 2023 | 47.93% |
| 2022 | 37.03% |
| 2021 | 48.32% |
| 2020 | -24.23% |
| 2019 | -82.68% |
| 2018 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $62.20 | 65.94% |
US
|
|
| $46.29 | 38.28% |
SE
|
|
| $171.04 | 30.37% |
FR
|
|
| $116.39 | 54.38% |
US
|
|
| $59.46 | 0.32% |
IT
|
